OBJECTIVE To report a case of an infant with endstage renal failure caused by primary hyperoxaluria. METHODS The review of the literature showed the rarity of the disease. In France, the prevalence is about 1.05/million and the incidence rate is 0.12/million/year. A survey, performed in international specialized centers in 1999, documented 78 cases in infants; in 14% of them the initial onset...

Atherosclerotic Renal Artery Stenosis (ARAS) is a common cause of secondary hypertension, especially in the elderly population, and is often associated with increased cardiovascular morbidity and mortality, as well as progression to chronic renal insufficiency [1,2]. Consequently, treatment options have been increasingly directed towards the preservation of renal function and reduction in the p...

BACKGROUND: Plasma B-type natriuretic peptide (BNP) is a diagnostic and prognostic marker in heart failure (HF). Although renal function is reported as an important clinical determinant, precise evaluations of the relationships of renal function with hemodynamic factors in determining BNP have not been performed. Therefore, we evaluated the association of plasma BNP concentrations with LV end-d...

Enteric hyperoxaluria can lead to renal failure. There have only been a few reports of renal transplantation as treatment of endstage renal disease secondary to enteric hyperoxaluria and results have been mixed. This report describes a patient with Crohn's disease who developed chronic renal failure from enteric hyperoxaluria. He subsequently had a successful renal transplant without any post-o...

Chronic kidney disease is an increasing public health problem. In the United States, the prevalence is estimated to be approximately 11% of the adult population. Chronic kidney disease may progress to end-stage renal failure, a condition associated with high morbidity and mortality. Diabetes mellitus (DM) is one of the main causes of kidney disease and endstage renal failure. In the United Stat...

Patients with end-stage renal disease (ESRD), whether on conservative, peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood lymphocytes and an increased cancer incidence, especially of the kidney. The damage is possibly due to accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic pro...